#ASCO22 – RCT: Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer.

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: DNA shed from colon cancers into bloodstream successfully guides chemotherapy after surgery – Helps clarify the benefit of chemotherapy in stage II cancers – Johns Hopkins Medicine

Commentary: ctDNA Effectively Detects When Adjuvant Chemo Is Avoidable in Stage II Colon Cancers – Cancer Network

Commentary on Twitter

DYNAMIC: Among patients with stage II colon cancer, a ctDNA-guided management approach reduced the use of adjuvant chemotherapy without increasing the risk of recurrence. #ASCO22 https://t.co/xXjXyPXRC9 pic.twitter.com/gvHMnGWbyE

— NEJM (@NEJM) June 4, 2022